DolPHIN2

Search

  • About DolPHIN 2
  • Research
    • Clinical trial
    • Qualitative research
    • Health Economics
    • Community Voices
  • Resources
  • News & Events
    • News
    • Events
    • Past events

Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.

image source: pexels

The DolPHIN 2 programme investigates the safe and effective use of dolutegravir for women who present with untreated HIV in late pregnancy

The team at the Infectious Diseases Institute, Kampala

DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.

0

How we work

About DolPHIN 2

Read about the challenges that the DolPHIN 2 project seeks to address and why.

The DolPHIN 2 Consortium

Learn more about our multinational research consortium, comprising partners in Europe and sub-Saharan Africa.

Community Voices

Collaboration with the community is at the heart of DolPHIN 2. Click here to learn more about our community engagement, and to hear from some of our study participants.

1

Resources

11 Aug 2022

Empower, Engage, Educate - Breastfeeding

Video
11 Aug 2022

Empower, Engage, Educate - Delivery

Video
11 Aug 2022

Empower, Engage, Educate - Male Involvement

Video
11 Aug 2022

Empower, Engage, Educate - Mumbwa

Video
View all Resources
1

News

The Ugandan Team Celebrates World Breastfeeding Week

08 Aug 2019

DolPHIN-2 presents primary outcome analysis at CROI 2019

05 Mar 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

WHO released a statement on 18 May 2018 relating to a potential safety issue affecting women living with HIV using dolutegravir at the time of conception.

20 Jun 2018
View all News and Events

@UoLDolPHIN2 on Twitter

RT @UNITAID: The @UoLDolphin2 programme investigates the safety and efficacy of dolutegravir in pregnant HIV+ women and their neonates. Find out more about the final 72-week postpartum results in @TheLancet: https://t.co/O9WmgzpDTu https://t.co/p59Zv3dlWC
1 month 1 week ago
We are recruiting a NIHR Academic Clinical Lecturer in Clinical Pharmacology and Therapeutics at University of Liverpool https://t.co/gRrI5C7LQ0
1 month 3 weeks ago
On #WorldAIDSDay we would like to thank all the participants for their time and commitment to the DolPHIN2 trial
2 months 4 days ago
RT @AdellineTwimu: Please follow the link below to join the forum through zoom; Dolutegravir in Pregnant HIV Mothers and their Noenates- (DoLPHIn 2) https://t.co/BW8V7GzVIn @IDIMakerere @UoLDolphin2 https://t.co/VNQIRcH5GS
3 months 2 days ago
RT @UNITAID: In sub-Saharan Africa, over 1 in 5 HIV-infected pregnant women are diagnosed in late pregnancy each year. @UoLDolphin2 investigates factors that influence late antenatal initiation and the adherence to and retention in combination antiretroviral therapy programmes in pregnancy. https://t.co/gds9CbxJGZ
3 months 1 week ago
RT @CatrionaWaitt: @UoLDolphin2 consortium meeting hosted by @livuninews. We've shown that it is possible to do policy - changing research with women in late pregnancy, and have built a strong, international multi disciplinary team. Great final discussion on the next steps. I am excited! @UNITAID https://t.co/LXi6eASMi0
3 months 1 week ago
The Uganda DolPHIN-2 team had a successful second day at #JASHC2022 promoting the effectiveness and acceptability of dolutegravir in late #pregnancy #HIV #clinicalresearch https://t.co/S0aVJXqUtH
4 months 1 week ago
The DolPHIN2 team from Uganda were at #JASHC2022 presenting results from our clinical trial and qualitative research that support the use of dolutegravir in #pregnancy #HIV #clinicaltrials https://t.co/eexJVR4Cmb
4 months 1 week ago
RT @LivUni: https://t.co/xG5H2J7uMI
4 months 3 weeks ago
RT @At_The_EQUATOR: #WorldBreastfeedingWeek2022 Breast milk is the best choice for the baby and the mother. Fathers have to step up and support their #breastfeeding partners. #BreastfeedingWeek #WBW2022 #BreastMilkDonation #educateandsupport @cgbanda @paulkgonza @livuninews @wellcometrust @okoboi25 https://t.co/dzIocX3nZe
6 months 5 days ago
RT @drlaurajwaters: #AIDS2022 @CatrionaWaitt summarising optimal DTG use in women - they key is COMMUNICATION & ONGOING DIALOGUE. Hell yes to that! This is a great slide https://t.co/zyWiuM1pBY
6 months 6 days ago
RT @CatrionaWaitt: @AIDS_conference #AIDS2022 @agenceANRS @UNITAID @UoLDolphin2 @modernart4sa exhibition in Global Village. Bringing art and film to creatively engage on many HIV related topics. The leaflets are great - come and visit! https://t.co/2PS2QWa8jP
6 months 1 week ago

The D2 Consortium

The DolPHIN 2 consortium is a multinational partnership comprising five research organisations and our funder, Unitaid.

University of Liverpool

Liverpool School of Tropical Medicine

Infectious Diseases Institute

University of Cape Town

Radboud University Medical Centre

Unitaid

Contact us

dolphin [dot] admin [dot] team [at] liverpool [dot] ac [dot] uk

ClinicalTrials.gov Identifier: NCT03249181

Follow us

  • Twitter
A Remora website by Manta Ray Media